- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02189109
The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma (GBM)
A Phase 1b Dose-finding, Pharmacokinetic and Pharmacodynamic Study of NVX-108 Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma Multiforme
This clinical trial is testing the safety, tolerability and effectiveness of NVX-108 administered via intravenous infusion in combination with standard radiation and chemotherapy.
NVX-108 is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- St. Vincents Hospital Sydney
-
-
South Australia
-
Adelaide, South Australia, Australia, 5042
- Flinders Medical Centre
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Nucleus Network
-
Melbourne, Victoria, Australia, 3121
- Epworth Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically-confirmed newly-diagnosed glioblastoma multiforme.
- No prior treatment for glioblastoma apart from surgical resection.
- No prior treatment for glioblastoma apart from surgical resection.
- Planned for 60 Gray of focal radiation administered in 30 fractions, concurrently with temozolomide chemotherapy.
- Manageable risks associated with potential radiation necrosis in the radiation field, based on size of the field and proximity to eloquent brain regions (as assessed by the investigator).
- Aged 18-70 years.
- ECOG performance status 0-2.
- Life expectancy of at least 3 months.
- If receiving glucocorticoid therapy, the dose must be stable over at least 7 days prior to study enrollment.
- Archived tumor tissue available for central review.
- Able to undergo gadolinium-enhanced MRI (Gd-MRI) scans.
- Baseline MRI performed within 14 days before starting study treatment, while on a stable glucocorticoid dose for at least 5 days before and during the imaging study.
Adequate hematologic, renal and hepatic function, as defined by:
Absolute neutrophil count (ANC) ≥ 1.5 109/L Platelet count ≥ 100 109/L Hemoglobin ≥ 90 g/L International normalized ratio (INR) and activated partial thromboplastin time (APTT) < 1.5 upper limit of normal (ULN) Plasma creatinine< 1.5 ULN Total bilirubin within normal limits (< 2.5 ULN if Gilbert's syndrome) AST and ALT < 2.5 ULN
- Patients who are women of childbearing potential or men (unless vasectomised) must agree to use a highly-effective method of birth control, such as hormonal contraceptive implants, combined oral contraceptives, an intrauterine device, a double-barrier method (eg. condom with a diaphragm) or abstinence, from study entry until 4 months after completing study therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Presence of leptomeningeal disease or multifocal glioblastoma that cannot be encompassed within a feasible and safe radiation field.
- Intracranial bleeding, except for stable grade 1 hemorrhage.
- Has not recovered from the adverse effects of surgical resection or biopsy, except for neurological deficits.
- Patients who have received any other investigational agent within 4 weeks before enrollment.
- Stroke or transient ischemic attack within 6 months before enrollment.
- Myocardial infarction within 6 months before enrollment, unstable angina, New York Heart Association class II or greater congestive heart failure, or uncontrolled hypertension (systolic BP > 160 mmHg and/or diastolic BP > 100 mmHg).
- Congenital long QT syndrome.
- Clinically-significant chronic obstructive pulmonary disease or asthma.
- Active major infection requiring treatment.
- A history of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ cancer or other solid tumors curatively treated with no evidence of disease for ≥ 2 years.
- Known infection with human immunodeficiency virus or hepatitis B or C virus.
- Current anticoagulant or antiplatelet therapy, except for prophylactic doses of low molecular weight heparins or low-dose aspirin.
- History of allergic reactions attributed to compounds of similar chemical composition to NVX-108.
- Women who are pregnant or breast feeding.
- Inability to comply with study procedures.
- History or evidence of any other clinically-significant condition that, in the opinion of the investigator, would pose a risk to subject safety or interfere with study procedures, evaluation or completion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation
NVX-108 (DDFP liquid emulsion) i.v. in conjunction with Radiation Treatment and Temozolimide.
0.05-0.35cc/kg.
|
0.2% emulsion administered i.v.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability of NVX-108 in Combination with Radiation and Temozolomide Defined by no Drug related Adverse Events (AE) in No More than 1 Patient per Treatment Group
Time Frame: 6 months
|
Adverse Events are considered to be neurological and hemodynamic
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression Free Survival at 6 months
Time Frame: 6 months
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Reduction Based on Gd-MRI
Time Frame: 4 months
|
First determination will be measured at 4 months
|
4 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jason Lickliter, MBBSPhDFRACP, Nucleus Network
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NVX108-GBM1B
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma Multiforme
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
University of UtahWithdrawnGlioblastoma Multiforme (GBM)United States
-
Sunnybrook Health Sciences CentreRecruitingGlioblastoma Multiforme, AdultCanada
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingGlioblastoma Multiforme, AdultChina
-
Polaris GroupRecruitingGlioblastoma Multiforme (GBM)Taiwan
-
University of IowaEisai Inc.TerminatedPrimary Glioblastoma MultiformeUnited States
Clinical Trials on NVX-108
-
NovavaxActive, not recruiting
-
Amma Owusu-Ansah, MDNuvOx LLC; Noguchi Memorial Institute for Medical ResearchWithdrawnSickle Cell Disease
-
Dow Pharmaceutical SciencesCompleted
-
University of California, San FranciscoCompletedProgressive Supranuclear Palsy | Corticobasal Degeneration Syndrome | Progressive Nonfluent Aphasia | Predicted Tauopathies, Including | Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17United States
-
SRI InternationalTaiho Pharmaceutical Co., Ltd.CompletedBreast CancerUnited States
-
The First Affiliated Hospital with Nanjing Medical...Guangzhou Lupeng Pharmaceutical Company LTD.; Newave Pharmaceutical IncRecruitingChronic Lymphocytic Leukemia | Non-Hodgkin LymphomaChina
-
University of California, Los AngelesMassachusetts General Hospital; Washington University School of Medicine; University... and other collaboratorsCompleted
-
Allon TherapeuticsCompletedMild Cognitive Impairment, So StatedUnited States
-
Dow Pharmaceutical SciencesCompletedOnychomycosisUnited States, Canada
-
Immune-Onc TherapeuticsRegeneron PharmaceuticalsActive, not recruiting